← back to search

Bingyang Shi

Columbia University · CN
Area of research
Molecular Biology · Biomedical Engineering
Research interest
Research interests include Nanoplatforms for cancer theranostics, RNA Interference and Gene Delivery, Nanoparticle-Based Drug Delivery, and Advanced biosensing and bioanalysis techniques.
h-index
53
citations
11,130
works
195
NIH funding
primary concept
Medicine
email

Recent publications

Nanoparticle-mediated targeting chimeras transform targeted protein degradation
Nature Nanotechnology 2026cited by 5position: contributordoi
High-Throughput Generation of Tumor Spheroids via Droplet Microfluidics for siRNA-Loaded Nanomedicine Assessment.
2026cited by 1position: contributordoi
Non-Invasive Brain Targeted Delivery of Cannabidiol for Alleviating Neuroinflammatory Disease.
2026cited by 0position: contributordoi
Restoration of p53 mRNA combined with BRD4 silencing by brain targeted nanocapsules achieves effective combinatorial treatment of glioblastoma.
2026cited by 0position: contributordoi
Clinical translation of nanomedicines for brain diseases: Current challenges and future directions.
2026cited by 0position: contributordoi
Two-dimensional NIR-II AIE nanotheranostic probes with ultralarge Stokes shifts for surgical navigation and ablation of glioma.
2026cited by 0position: contributordoi
Advances in targeted protein degradation for cancer immunotherapy
Cell Biomaterials 2026cited by 0position: contributordoi
Artificial-intelligence-driven rational design of nanoparticle-mediated targeted protein degradation
Cell Biomaterials 2026cited by 0position: contributordoi
Biomimetic Nanovaccine Integrating Dendritic Cell Exosomes with Tumor Cell Membranes for Sustained Prophylaxis Against Glioblastoma
Advanced Functional Materials 2026cited by 0position: contributordoi
A Brain-Targeting NIR-II Polymeric Phototheranostic Nanoplatform toward Orthotopic Drug-Resistant Glioblastoma.
2025cited by 13position: contributordoi
Glioblastoma Cell Derived Exosomes as a Potent Vaccine Platform Targeting Primary Brain Cancers and Brain Metastases.
2025cited by 10position: contributordoi
Advanced nanoparticle engineering for precision therapeutics of brain diseases.
2025cited by 10position: contributordoi
Inhibition of ICAM1 diminishes stemness and enhances antitumor immunity in glioblastoma via β-catenin/PD-L1 signaling.
2025cited by 4position: contributordoi
Amino acid transporters mediate autonomous delivery of nanoparticle vehicles into living plants.
2025cited by 1position: contributordoi
Glycyrrhetinic acid functionalized polyamidoamine dendrimers for targeted gene delivery in liver cancer.
2025cited by 0position: contributordoi
Natural Ginger-Derived Exosomes as Effective Therapeutics for Glioblastoma.
2025cited by 0position: contributordoi
Tannic Acid-Iron Complex-Based Nanozyme Ameliorates Parkinson's Disease via Relieving Oxidative Stress and Neuroinflammation.
2025cited by 0position: contributordoi
MAGL targeted PROTAC degrader simultaneously enhances P53 for synergistic treatment of glioblastoma stem cell.
2025cited by 0position: contributordoi
Integrated proteogenomic characterization of glioblastoma evolution
Cancer Cell 2024cited by 86position: middledoi
Targeted protein degradation via cellular trafficking of nanoparticles
Nature Nanotechnology 2024cited by 72position: contributordoi
Integrated proteogenomic characterization of glioblastoma evolution.
2024cited by 69position: contributordoi
A one-two punch targeting reactive oxygen species and fibril for rescuing Alzheimer's disease.
2024cited by 36position: contributordoi
Bio-Nano Toolbox for Precision Alzheimer's Disease Gene Therapy.
2024cited by 12position: contributordoi
CD97 maintains tumorigenicity of glioblastoma stem cells via mTORC2 signaling and is targeted by CAR Th9 cells.
2024cited by 9position: contributordoi
Small Scale, Big Impact: Nanotechnology-Enhanced Drug Delivery for Brain Diseases.
2024cited by 7position: contributordoi
Exosomes based strategies for brain drug delivery.
2023cited by 145position: contributordoi
Cancer cell-mitochondria hybrid membrane coated Gboxin loaded nanomedicines for glioblastoma treatment.
2023cited by 99position: contributordoi
Near-Infrared Aggregation-Induced Emission Luminogens for In Vivo Theranostics of Alzheimer's Disease.
2023cited by 49position: contributordoi
Liquid-liquid phase separation of amyloid-β oligomers modulates amyloid fibrils formation.
2023cited by 48position: contributordoi
IGFBP5 is an ROR1 ligand promoting glioblastoma invasion via ROR1/HER2-CREB signaling axis.
2023cited by 40position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 48 papers (2019–2026)Yan Zou · Hangzhou Medical College24 papers (2019–2025)Meng Zheng · Henan University Huaihe Hospital and Huaihe Clinical Institute21 papers (2019–2026)Albert Lee · Cancer Research Institute13 papers (2017–2021)Jia Li · Shenyang Pharmaceutical University8 papers (2020–2021)David B. Lovejoy · Macquarie University6 papers (2019–2022)Wei Tao · Brigham and Women's Hospital6 papers (2019–2022)Meng Zheng · Kunming University of Science and Technology5 papers (2019–2022)Fawad U Rehman · Henan University5 papers (2020–2023)Yang Liu · Jinhua Academy of Agricultural Sciences5 papers (2020–2026)Yong Zhong · Henan University5 papers (2021–2026)Wei Tao · Brigham and Women's Hospital4 papers (2017–2021)Pir Muhammad · Hainan Medical University4 papers (2020–2022)Yiqing Lu · Ming Chi University of Technology4 papers (2019–2025) · 4 papers (2019–2021)Shihui Wen · Eastern Institute of Technology, Ningbo4 papers (2020–2022)Kam W. Leong · University of Missouri4 papers (2020–2026)Dayong Jin · Shanghai Sixth People's Hospital4 papers (2020–2022)Adam K. Walker · UNSW Sydney3 papers (2017–2021)Stephanie L. Rayner · Macquarie University3 papers (2017–2021)